Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Coverage (6)

• Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC Yahoo Finance · 21d ago
• Can Pfizer (NYSE:PFE) Clear Its Latest Oncology Hurdle? Kalkine Media · 21d ago
• Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial CancerNetwork · 21d ago
• Pfizer drug acquired in Seagen deal disappoints in lung cancer study BioPharma Dive · 21d ago
• Sigvotatug Vedotin Fails to Improve OS in Advanced, Pretreated Nonsquamous NSCLC OncLive · 21d ago
• Pfizer's $43B Seagen bet sours further as ADC fails in late-stage lung cancer trial Endpoints News · 21d ago

Related trends